Inclisiran provides additional LDL Cholesterol-Lowering Benefit for the selected patients.

01 Sep 2023
Inclisiran provides additional LDL Cholesterol-Lowering Benefit for the selected patients.
Consultant Cardiologist Dr Yew Kuan Leong elaborates on the efficacy and safety of inclisiran, a new LDL cholesterol-lowering injectable medication now available in Malaysia, and the target group of patients benefiting from the additional LDL cholesterol-lowering therapy.
 Sponsored as an educational program by Novartis Corporation (Malaysia) Sdn Bhd 

Related MIMS Drugs

Resources

MY-NOV-320

MY-NOV-320

MY-NOV-320

MY-NOV-320